Company Overview

ASP Isotopes Inc. (ticker: ASPI) is a U.S.-listed advanced materials company focused on the production and commercialization of highly enriched isotopes used in the nuclear energy, medical diagnostics and therapeutics, and industrial markets. The company’s core business is the enrichment of stable and radioactive isotopes that are difficult to source through traditional centrifuge or reactor-based methods. Its revenue model is centered on long-term supply agreements, custom isotope production, and strategic partnerships with nuclear fuel cycle participants and healthcare suppliers.

The company positions itself through proprietary enrichment technology designed to offer lower capital intensity, enhanced safety, and scalability compared to conventional enrichment approaches. ASP Isotopes traces its origins to private isotope technology development efforts before becoming publicly listed in 2022, using its public capital base to accelerate commercialization, expand enrichment capacity, and pursue strategic acquisitions aligned with the nuclear fuel and medical isotope supply chains.

Business Operations

ASP Isotopes operates primarily through vertically integrated isotope production and enrichment activities, generating revenue from the sale of enriched isotopes to nuclear fuel developers, medical isotope distributors, and research institutions. Its principal operating focus includes isotope enrichment services, nuclear fuel-related isotopes, and medical-grade isotope production, with development-stage facilities supporting both pilot-scale and commercial output.

Operations span both domestic and international assets, with significant technical and operational infrastructure located outside the United States. The company controls proprietary laser-based isotope enrichment technology and associated intellectual property, which underpins its competitive positioning. Its operating structure includes wholly owned subsidiaries that manage technology development, facility construction, and regional commercialization efforts; however, public disclosures indicate that several projects remain in pre-revenue or early commercialization phases.

Strategic Position & Investments

Strategically, ASP Isotopes is focused on becoming a critical supplier within emerging nuclear fuel ecosystems, particularly those supporting advanced and next-generation reactor designs, as well as expanding access to scarce medical isotopes. Growth initiatives emphasize capacity buildout, long-term offtake agreements, and alignment with government-supported nuclear and healthcare infrastructure programs.

The company has made targeted investments in specialized isotope production facilities and has acquired or formed subsidiaries to localize operations near key technical talent pools and end markets. It continues to invest in enrichment technologies applicable to uranium-adjacent isotopes and non-uranium applications, while evaluating opportunities in adjacent nuclear materials and radiopharmaceutical supply chains. Certain announced initiatives remain subject to regulatory approvals and customer contracting, and timelines vary based on external factors.

Geographic Footprint

ASP Isotopes is headquartered in the United States, with its corporate base in Florida, while maintaining a substantial operational presence in Southern Africa, where it conducts technology development and enrichment activities. This international footprint reflects strategic access to skilled technical labor, favorable infrastructure conditions, and proximity to nuclear-related industrial partners.

The company’s market reach spans North America, Europe, and parts of Africa, with commercial relationships and development efforts targeting customers in global nuclear energy and healthcare markets. While revenues to date are primarily concentrated in early-stage or contracted arrangements, management has indicated an intention to scale international deliveries as facilities transition to full commercial operation.

Leadership & Governance

ASP Isotopes is led by its founder, with governance structured around a board and executive team experienced in nuclear technology, advanced materials, and public company operations. Leadership emphasizes long-term supply reliability, technological differentiation, and disciplined capital deployment aligned with regulated end markets.

Key executives include:

• Paul Mann – Chief Executive Officer
• John S. Mitchell – Chief Financial Officer
• Clive Cowley – Chief Operating Officer
• Robert E. E. Mann – Chairman of the Board

Management’s strategic vision centers on establishing ASP Isotopes as a trusted, Western-aligned supplier of critical isotopes, supporting energy security, healthcare resilience, and industrial innovation.